Inogen stock sharpens its focus with a USD 25 million sale

Published on 10/08/2026 at 04:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Inogen stock carries a USD 12.00 average target from two analysts, while second-quarter revenue reached USD 95.1 million. The rental unit generated USD 24.3 million in six months.

INGN, US45780L1044, Illustration mit AI erstellt.

Inogen stock is tied to a USD 25 million strategic sale as the respiratory-device maker reshapes its business around product sales and distribution. Inogen announced the Rotech transaction on September 30, 2026, alongside a long-term supply agreement for oxygen concentrators.

USD 25 million sale changes the mix

Rotech is set to acquire specified U.S. oxygen rental assets for cash consideration of up to USD 25 million, with completion expected in the fourth quarter of 2026, subject to customary conditions. The deal also moves the rental business into discontinued operations beginning with Inogen's third-quarter 2026 results, pending final accounting treatment.

The strategic trade-off is visible in the rental figures. The unit generated USD 24.3 million of revenue in the first half of 2026, down 9.8 percent from the comparable period, while Inogen said the transactions are expected to increase its revenue growth rate and adjusted operating income, according to Inogen.

Q2 revenue reached USD 95.1 million

For the quarter ended June 30, 2026, Inogen reported revenue of USD 95.1 million and adjusted EBITDA of USD 2.4 million. Cash, cash equivalents, marketable securities and restricted cash totaled USD 106.8 million at the same date, according to Inogen.

The quarter also marked an improvement from the first quarter's USD 85.1 million revenue and USD 8.3 million net loss. Second-quarter net loss narrowed to USD 3.9 million, while diluted GAAP loss per share improved to USD 0.14 from USD 0.30 in the prior quarter.

Analysts see a wider valuation gap

StockAnalysis lists a Buy consensus from two analysts and an average price target of USD 12.00. Against the USD 5.82 reference price, that target lies 106.19 percent above the price.

A separate analyst update on October 1, 2026, kept the company in a constructive research frame: Markets Insider reported that Needham analyst Michael Matson maintained a Buy rating with a USD 12.00 price target. The central test is whether the supply agreement can replace the rental unit's declining revenue with faster product growth.

INGN remains below its yearly high

Inogen was trading at USD 5.82 on Nasdaq on October 7, 2026, at 12:14 p.m. ET, up 0.78 percent from the prior close of USD 5.77. The session range was USD 5.71 to USD 5.88, the 52-week range was USD 5.05 to USD 9.13, volume was 77,490 shares and market capitalization was USD 157.4 million.